A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma
Phase 1
Active, not recruiting
- Conditions
- multiple myeloma
- Registration Number
- 2023-503620-60-00
- Lead Sponsor
- Janssen - Cilag International
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruitment ended
- Sex
- Not specified
- Target Recruitment
- 49
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Universitair Ziekenhuis Gent
🇧🇪Gent, Belgium
Antwerp University Hospital
🇧🇪Edegem, Belgium
Centre Hospitalier Universitaire De Rennes
🇫🇷Rennes, France
Institut Universitaire Du Cancer Toulouse-Oncopole
🇫🇷Toulouse, France
Centre Hospitalier Universitaire De Bordeaux
🇫🇷Pessac, France
Centre Hospitalier Universitaire De Nantes
🇫🇷Nantes, France
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
University Hospital Maastricht
🇳🇱Maastricht, Netherlands
Universitair Ziekenhuis Gent🇧🇪Gent, BelgiumNicolas KintSite contact+3293322125Nicolas.Kint@uzgent.be